Hyloris Pharmaceuticals Reports Full Year 2022 Earnings

Hyloris Pharmaceuticals (EBR:HYL) Full Year 2022 Results

Key Financial Results

• Net loss: €10.8m (loss narrowed by 7.0% from FY 2021).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Hyloris Pharmaceuticals Earnings Insights

Looking ahead, revenue is forecast to grow 83% p.a. on average during the next 3 years, compared to a 5.6% growth forecast for the Pharmaceuticals industry in Europe.

Performance of the market in Belgium.

The company's shares are up 4.1% from a week ago.

Risk Analysis

Before you take the next step you should know about the 2 warning signs for Hyloris Pharmaceuticals that we have uncovered.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.